- Home
- PETZ vs ICU Comparison
PETZ vs ICU Comparison
Compare PETZ & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- ICU
- Stock Information
- Founded
- PETZ 2002
- ICU 2018
- Country
- PETZ China
- ICU United States
- Employees
- PETZ N/A
- ICU N/A
- Industry
- PETZ Steel/Iron Ore
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- ICU Health Care
- Exchange
- PETZ Nasdaq
- ICU Nasdaq
- Market Cap
- PETZ 10.3M
- ICU 10.4M
- IPO Year
- PETZ 2017
- ICU N/A
- Fundamental
- Price
- PETZ $0.95
- ICU $1.19
- Analyst Decision
- PETZ
- ICU
- Analyst Count
- PETZ 0
- ICU 0
- Target Price
- PETZ N/A
- ICU N/A
- AVG Volume (30 Days)
- PETZ 11.7K
- ICU 144.0K
- Earning Date
- PETZ 04-28-2025
- ICU 05-14-2025
- Dividend Yield
- PETZ N/A
- ICU N/A
- EPS Growth
- PETZ N/A
- ICU N/A
- EPS
- PETZ 0.26
- ICU N/A
- Revenue
- PETZ $563,726.00
- ICU $428,000.00
- Revenue This Year
- PETZ N/A
- ICU $648.15
- Revenue Next Year
- PETZ N/A
- ICU $100.00
- P/E Ratio
- PETZ $4.65
- ICU N/A
- Revenue Growth
- PETZ 74664.72
- ICU N/A
- 52 Week Low
- PETZ $0.65
- ICU $1.11
- 52 Week High
- PETZ $1.74
- ICU $13.85
- Technical
- Relative Strength Index (RSI)
- PETZ 47.17
- ICU 36.82
- Support Level
- PETZ $0.86
- ICU $1.13
- Resistance Level
- PETZ $0.96
- ICU $1.34
- Average True Range (ATR)
- PETZ 0.07
- ICU 0.07
- MACD
- PETZ 0.01
- ICU 0.00
- Stochastic Oscillator
- PETZ 75.39
- ICU 28.57
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.